Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab
Taverna, J.A.; Lerner, A.; Bhawan, J.; Demierre, M.-F.
Journal of Drugs in Dermatology Jdd 6(7): 731-732
2007
ISSN/ISBN: 1545-9616 PMID: 17763598 Document Number: 15066
Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.
Document emailed within 1 workday
